Dataset Information

Development of antibody-drug conjugates in cancer: Overview and prospects.

ABSTRACT: In recent years, remarkable breakthroughs have been reported on antibody-drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as one of the fastest-growing domains in the realm of anticancer drugs, demonstrating their efficacy in treating a wide array of malignancies. Nonetheless, there is still an unmet clinical need for wider application, better efficacy, and fewer side effects of ADCs. An ADC generally comprises an antibody, a linker and a payload, and the combination has profound effects on drug structure, pharmacokinetic profile and efficacy. Hence, optimization of the key components provides an opportunity to develop ADCs with higher potency and fewer side effects. In this review, we comprehensively reviewed the current development and the prospects of ADC, provided an analysis of marketed ADCs and the ongoing pipelines globally as well as in China, highlighted several ADC platforms and technologies specific to different pharmaceutical enterprises and biotech companies, and also discussed the new related technologies, possibility of next-generation ADCs and the directions of clinical research.

SUBMITTER: Ruan DY

PROVIDER: S-EPMC10794012 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development of antibody-drug conjugates in cancer: Overview and prospects.

Ruan Dan-Yun DY Wu Hao-Xiang HX Meng Qi Q Xu Rui-Hua RH

Cancer communications (London, England) 20231230 1

In recent years, remarkable breakthroughs have been reported on antibody-drug conjugates (ADCs), with 15 ADCs successfully entering the market over the past decade. This substantial development has positioned ADCs as one of the fastest-growing domains in the realm of anticancer drugs, demonstrating their efficacy in treating a wide array of malignancies. Nonetheless, there is still an unmet clinical need for wider application, better efficacy, and fewer side effects of ADCs. An ADC generally com ...[more]

PMID: 38159059

Similar Datasets

Project description:Background and objectiveAs the most common cancer to progress to brain metastases (BMs), lung cancer presents with intracranial involvement in approximately 20% of patients at the time of diagnosis and lung cancer BMs constitute approximately half of all BMs. The current clinical strategy for managing lung cancer BMs involves a combination of systemic anticancer therapies with local radiation or surgical interventions. The efficacy of systemic treatments is often constrained by the blood-brain barrier (BBB) and the poor inhibition effect of the drug itself. Despite these treatments, the median survival for patients with lung cancer BMs frequently does not exceed 2 years, underscoring the urgent need for novel and effective therapeutic approaches. Antibody-drug conjugate (ADC) consists of three components: monoclonal antibodies, payload, and linkers. Novel ADCs have demonstrated therapeutic advantages in a variety of tumors, including BMs. This review aims to summarize the latest advancements of ADCs in lung cancer BM.MethodsFor this review, we searched the literature published in the field of ADCs for lung cancer BMs over the past 10 years.Key content and findingsNew-generation ADCs, represented by trastuzumab deruxtecan (T-DXd) and others, have demonstrated prominent intracranial antitumor activities and have shown significant therapeutic advantages on lung or breast cancer BMs in both preclinical and clinical studies. Several factors may contribute to the efficacies of ADCs in the intracranial cancers including specific payload, a higher and uniform drug:antibody ratio (DAR) as well as potent bystander effect. Whether intracranial tumors express these target antigens should also be taken into consideration.ConclusionsADCs have demonstrated promising antitumor activities in non-small cell lung cancer (NSCLC) patients with BMs and could offer a new systemic treatment option for this subset population of patients. More research exploring the efficacy, safety and mechanism of ADCs in BMs are needed. Combining ADCs with conventional treatments for BMs, such as radiotherapy and immunotherapy, may be a new direction for future treatment.

Dataset Information

Development of antibody-drug conjugates in cancer: Overview and prospects.

Publications

Development of antibody-drug conjugates in cancer: Overview and prospects.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets